logo

For the Inventor, By the Inventor

Dallas, TX, United States of America

John D Buynak

This inventor holds 21 USPTO granted patents and 2 published patent applications, primarily in Antibiotic Development. Top assignees: Research Corporation Technologies, Inc., Southern Methodist University, University of Central Florida Research Foundation Inc.. Active years: 1997-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John D Buynak. Retrieved from https://idiyas.com/inventor/john-d-buynak

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 

% Patents Active = 57.1

Average Co-Inventor Count = 2.5

ph-index = 5

Forward Citations = 49(Granted Patents)


Company Filing History:

goldMedal11 out of 366 
 
Research Corporation Technologies, Inc.
 patents
silverMedal8 out of 119 
 
Southern Methodist University
 patents
bronzeMedal2 out of 1,376 
 
University of Central Florida Research Foundation Inc.
 patents
4. 1 out of 1 
 
Alamx, LLC
 patent
5. 1 out of 834,570 
Other
 patents
where one patent can have more than one assignee

Years Active: 1997-2022

Loading Chart...
Areas of Expertise:
Beta-Lactamase Inhibitors
Carbapenem Antibiotics
Mycobacterium Tuberculosis
Penicillanic Acid Derivatives
Cephem Compounds
Serine Lactamases
Metallo-Lactamases
Alkylidene Compounds
Antibiotic Resistance
Compositions
Inhibitory Compounds
Elastase Activity
21 patents (USPTO):Explore Patents
1. 11234966 - C5-substituted carbapenem antibiotics, compositions containing such compounds, and methods of use in treatment of mycobacterium tuberculosis and non-tubercular mycobacteria (2022-02-01),
2. 10702501 - C5-substituted carbapenem antibiotics, compositions containing such compounds, and methods of use in treatment ofand non-tubercular mycobacteria (2020-07-07),
3. 10519161 - Methods of generating beta-lactamase resistant carbapenem compounds (2019-12-31),
4. 8575144 - Beta-lactamase inhibitory compounds (2013-11-05),
5. 8299051 - Beta-lactamase inhibitory compounds (2012-10-30),
6. 7488724 - 7-alkylidene-3-substituted-3-cephem-4-carboxylates as beta-lactamase inhibitors (2009-02-10),
7. 7125986 - Penicillanic acid derivative compounds and methods of making (2006-10-24),
8. 7022691 - Inhibitors of serine and metallo-β-lactamases (2006-04-04),
9. 6916801 - 7-Alkylidene-3-substituted-3-cephem-4-carboxylates as β-lactamase inhibitors (2005-07-12),
10. 6906054 - Compositions for inhibiting beta-lactamase (2005-06-14),
11. 6770759 - Penicillanic acid derivative compounds and methods of making (2004-08-03),
12. 6599892 - 7-alkylidene cephalosporanic acid derivatives and methods of using the same (2003-07-29),
13. 6436398 - 2 &bgr;-substituted-6-alkylidene penicillanic acid derivatives as &bgr;-lactamase inhibitors (2002-08-20),
14. 6407091 - &bgr;-lactamase inhibiting compounds (2002-06-18),
15. 6303592 - 7-alkylidene cephalosporanic acid derivatives and methods of using the same (2001-10-16),

Sure, here is the article:

Title: The Inventor John D Buynak: A Pioneer in Antibiotic Innovations

Introduction:

John D Buynak, a distinguished inventor based in Dallas, TX, has made significant contributions to the field of antibiotics with a total of 21 patents to his name.

Latest Patents:

Among his latest patents is the groundbreaking invention of C5-substituted carbapenem antibiotics. This invention encompasses a composition, method of making, and method of using a novel C5-substituted carbapenem antibiotic, which shows promise in the treatment of mycobacterium tuberculosis and non-tubercular mycobacteria.

Career Highlights:

John D Buynak has lent his expertise to renowned institutions such as Research Corporation Technologies, Inc. and Southern Methodist University, where he has played a pivotal role in shaping the landscape of antibiotic innovations.

Collaborations:

Throughout his career, John D Buynak has collaborated with esteemed professionals in the field, including Akireddy Srinivasa Rao and Venkata Ramana Doppalapudi, fostering a culture of innovation and excellence.

Conclusion:

In conclusion, John D Buynak's relentless pursuit of innovation in the realm of antibiotics underscores his commitment to advancing healthcare solutions. His numerous patents and collaborations stand as a testament to his remarkable contributions to the field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…